Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Compounded tirzepatide is available in non-injection formats ... Section 5 – User Journey and Market Tone Public discussions ...

Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

An injection drug known as tirzepatide, already approved by the FDA for treating Type 2 diabetes, is likely to gain approval for weight loss treatment this year. Here's what to know.

Tirzepatide: A dual-acting medication that combines GLP-1 and GIP ... Tirzepatide is newer to the market and may be less widely available or more expensive than semaglutide.

Eli Lilly is cutting the price of its popular weight-loss drug to compete with counterfeit versions. Zepbound will be sold for $399 to $549 a month, compared to a previous list price of $1,059.

Eli Lilly's weight-loss drug Zepbound (tirzepatide) is facing a shortage in the U.S. due to increased demand, according to the FDA.

The global anti-obesity drugs market is projected to grow from $12.8 billion in 2024 to $104.9 billion by 2035, at a CAGR of 21.1%. The market is driven by GLP-1 agonists, small molecules, and ...

Summary. This week Lilly surpassed Johnson & Johnson to become the world's largest Pharma by market cap. That is quite astonishing given JNJ drove $95bn of revenues last year, compared to Lilly's ...